Paper32101732
Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis.
Kumar R and 30 others. Cell Rep, 2020. Cited by 55 papers, by iCite.
Cite this record
ConductScience Library. Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis. Papers, record 32101732. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32101732
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immunity | Major topic |
| Interferon Type I | Major topic |
| Leishmaniasis, Visceral | Major topic |
| Parasites | Major topic |
| Amphotericin B | |
| Animals | |
| CD4-Positive T-Lymphocytes | |
| Cytokines | |
| Dendritic Cells | |
| Epitopes | |
| Humans | |
| Inflammation | |
| Interferon-gamma | |
| Mice, Inbred C57BL | |
| Nitriles | |
| Pyrazoles | |
| Pyrimidines | |
| Receptor, Interferon alpha-beta | |
| Signal Transduction |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P50 AI074321 | NIAID NIH HHS | United States | P50AI074321 | PubMed and NIH | NIH RePORTER |
| U19 AI074321 | NIAID NIH HHS | United States | P50AI074321 | PubMed and NIH | NIH RePORTER |
| U19AI074321 | NIH | NIH RePORTER | |||
| ZIAAI000494 | NIH | NIH RePORTER |
References92
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25129481 | Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. | Nat Med | 2014 | https://conductscience.org/library/papers/25129481 | PubMed |
| 2 | 24876851 | Strategies to overcome antileishmanial drugs unresponsiveness. | J Trop Med | 2014 | https://conductscience.org/library/papers/24876851 | PubMed |
| 3 | 10652464 | Organ-specific immune responses associated with infectious disease. | Immunol Today | 2000 | https://conductscience.org/library/papers/10652464 | PubMed |
| 4 | 28584007 | T Cell-Derived IL-10 Impairs Host Resistance to Mycobacterium tuberculosis Infection. | J Immunol | 2017 | https://conductscience.org/library/papers/28584007 | PubMed |
| 5 | 28439019 | Type I interferons induced by endogenous or exogenous viral infections promote metastasis and relapse of leishmaniasis. | Proc Natl Acad Sci U S A | 2017 | https://conductscience.org/library/papers/28439019 | PubMed |
| 6 | 24789914 | Type I IFN signaling in CD8- DCs impairs Th1-dependent malaria immunity. | J Clin Invest | 2014 | https://conductscience.org/library/papers/24789914 | PubMed |
| 7 | 29167671 | Immune Checkpoint Targets for Host-Directed Therapy to Prevent and Treat Leishmaniasis. | Front Immunol | 2017 | https://conductscience.org/library/papers/29167671 | PubMed |
| 8 | 24625550 | Disseminated tuberculosis associated with ruxolitinib. | Leukemia | 2014 | https://conductscience.org/library/papers/24625550 | PubMed |
| 9 | 17115899 | Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. | J Interferon Cytokine Res | 2006 | https://conductscience.org/library/papers/17115899 | PubMed |
| 10 | 25352846 | The Regulation of CD4(+) T Cell Responses during Protozoan Infections. | Front Immunol | 2014 | https://conductscience.org/library/papers/25352846 | PubMed |
| 11 | 24470592 | Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. | Blood | 2014 | https://conductscience.org/library/papers/24470592 | PubMed |
| 12 | 8021511 | Role and effect of TNF-alpha in experimental visceral leishmaniasis. | J Immunol | 1994 | https://conductscience.org/library/papers/8021511 | PubMed |
| 13 | 29741608 | JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. | Brain | 2018 | https://conductscience.org/library/papers/29741608 | PubMed |
| 14 | 22539670 | RNA-SeQC: RNA-seq metrics for quality control and process optimization. | Bioinformatics | 2012 | https://conductscience.org/library/papers/22539670 | PubMed |
| 15 | 22375970 | JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22375970 | PubMed |
| 16 | 606433 | Regulation of Leishmania populations within the host. I. the variable course of Leishmania donovani infections in mice. | Clin Exp Immunol | 1977 | https://conductscience.org/library/papers/606433 | PubMed |
| 17 | 15361245 | The immunopathology of experimental visceral leishmaniasis. | Immunol Rev | 2004 | https://conductscience.org/library/papers/15361245 | PubMed |
| 18 | 25183962 | Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects. | Front Immunol | 2014 | https://conductscience.org/library/papers/25183962 | PubMed |
| 19 | 30355785 | Distinct Roles for CD4+ Foxp3+ Regulatory T Cells and IL-10-Mediated Immunoregulatory Mechanisms during Experimental Visceral Leishmaniasis Caused by Leishmania donovani. | J Immunol | 2018 | https://conductscience.org/library/papers/30355785 | PubMed |
| 20 | 22157630 | Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. | Nat Immunol | 2011 | https://conductscience.org/library/papers/22157630 | PubMed |
Cited by42
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 55 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42734842 | Visceral leishmaniasis: an integrated review of resistance mechanisms, host immunometabolism, and next generation therapeutics. | Inflammopharmacology | 2026 | https://conductscience.org/library/papers/42734842 | PubMed |
| 42564585 | A single-cell transcriptomic atlas of peripheral blood immune cells spanning progressive canine leishmaniosis. | iScience | 2026 | https://conductscience.org/library/papers/42564585 | PubMed |
| 42410916 | Gardiquimod Nanoemulsion Targets Cutaneous Leishmaniasis Lesions Reducing Systemic Toxicity and Parasite Burden. | Adv Healthc Mater | 2026 | https://conductscience.org/library/papers/42410916 | PubMed |
| 42373718 | Cathepsin G and neutrophil elastase control Leishmania infantum parasitism through TLRs-dependent induction of IFN-α and TNF-α. | Commun Biol | 2026 | https://conductscience.org/library/papers/42373718 | PubMed |
| 42086915 | Human sand fly challenge elicits saliva-specific innate and type 1-polarized immunity that promotes Leishmania killing. | Commun Biol | 2026 | https://conductscience.org/library/papers/42086915 | PubMed |
| 42020513 | Lymphocyte-mediated immune responses to Leishmania infection. | Nat Rev Immunol | 2026 | https://conductscience.org/library/papers/42020513 | PubMed |
| 41546136 | Sex in Immune Cells and Parasitic Diseases - A Complex Relationship. | Immunol Rev | 2026 | https://conductscience.org/library/papers/41546136 | PubMed |
| 41446132 | A single-cell transcriptomic atlas of peripheral blood immune cells spanning progressive canine leishmaniosis. | bioRxiv | 2025 | https://conductscience.org/library/papers/41446132 | PubMed |
| 41321641 | Persistent myeloid cell reprogramming despite miltefosine treatment in leishmania-infected macaques. | iScience | 2025 | https://conductscience.org/library/papers/41321641 | PubMed |
| 41266459 | Leishmaniasis. | Nat Rev Dis Primers | 2025 | https://conductscience.org/library/papers/41266459 | PubMed |
| 40489555 | Vertical transmission of Leishmania donovani with placental degeneration in the pregnant mouse model of visceral leishmaniasis. | PLoS Negl Trop Dis | 2025 | https://conductscience.org/library/papers/40489555 | PubMed |
| 40393992 | Type I interferon drives T cell cytotoxicity by upregulation of interferon regulatory factor 7 in autoimmune kidney diseases in mice. | Nat Commun | 2025 | https://conductscience.org/library/papers/40393992 | PubMed |
| 40196468 | Human sand fly challenge elicits saliva-specific innate and TH1-polarized immunity that promotes Leishmania killing. | bioRxiv | 2025 | https://conductscience.org/library/papers/40196468 | PubMed |
| 40185735 | Innate biosignature of treatment failure in human cutaneous leishmaniasis. | Nat Commun | 2025 | https://conductscience.org/library/papers/40185735 | PubMed |
| 40169598 | Kupffer cell and recruited macrophage heterogeneity orchestrate granuloma maturation and hepatic immunity in visceral leishmaniasis. | Nat Commun | 2025 | https://conductscience.org/library/papers/40169598 | PubMed |
| 39702382 | Downregulation of IRF7-mediated type-I interferon response by LmCen-/- parasites is necessary for protective immunity. | NPJ Vaccines | 2024 | https://conductscience.org/library/papers/39702382 | PubMed |
| 38817668 | A parasite odyssey: An RNA virus concealed in Toxoplasma gondii. | Virus Evol | 2024 | https://conductscience.org/library/papers/38817668 | PubMed |
| 38724594 | Silver and gold nanoparticles as a novel approach to fight Sarcoptic mange in rabbits. | Sci Rep | 2024 | https://conductscience.org/library/papers/38724594 | PubMed |
| 38408097 | Altered IL-7 signaling in CD4+ T cells from patients with visceral leishmaniasis. | PLoS Negl Trop Dis | 2024 | https://conductscience.org/library/papers/38408097 | PubMed |
| 38362504 | Synthetic biology for combating leishmaniasis. | Front Microbiol | 2024 | https://conductscience.org/library/papers/38362504 | PubMed |
Genes24
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32101732
GET https://conductscience.org/api/papers/v1/32101732/authors?page=2